Saverio Alberti
University G. D' Annunzio, Italy
- Orcid: 0000-0002-4647-6042
- Publications: N/A
- Citations: N/A
- Keywords: Trop-2, breast cancer, colon cancer, immunotherapy, cell signaling
Short Bio
- Head of Medical Genetics, University of Messina, former Co-Director, Cancer Pathology, Foundation Chieti University. He obtained his MD degree cum laude, specialty in Clinical Oncology, Ferrara University, Italy, PhD in Pharmacological Research, Institute Mario Negri, Milano, Italy with Silvio Garattini, Fellow in Genetics, after 4-year post-doc with Luca Cavalli Sforza, Human Genetics, Len Herzenberg, Immunogenetics-Flow cytometry (Stanford). Saverio Alberti spent sabbaticals c/o Sir Peter Medawar, Nobel Prize laureate, CRC (Harrow, UK), Hiromitsu Nakauchi, HFSI (Tsukuba, Japan), Joseph Schlessinger, New York University, Ivan Morrison, ILRAD (Nairobi, Kenia). In 2012 he was Founding Member, then CEO, Oncoxx Biotech, Chieti, Italy. Mediterranea Theranostic followed in 2017. Saverio Alberti is leader in the field of research on Trop molecules. His research group cloned the Trop-1, Trop-2 genes, identified their function as stimulators of tumor cell growth and metastasis, and cause of rare genetic diseases, tufting enteropathy, corneal amyloid dystrophy. Saverio Alberti holds 14 families of patents on cancer therapeutics.
